Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo

详细信息    查看全文

• 作者：Bin Chen ; Saurabh G. Roy ; Ryan J. McMonigle ; Andrew Keebaugh ; Alison N. McCracken ; Elizabeth Selwan ; Rebecca Fransson ; Daniel Fallegger ; Andrea Huwiler ; Michael T. Kleinman ; Aimee L. Edinger ; Stephen Hanessian
• 刊名：ACS Chemical Biology
• 出版年：2016
• 出版时间：February 19, 2016
• 年：2016
• 卷：11
• 期：2
• 页码：409-414
• 全文大小：364K
• ISSN：1554-8937

文摘

FTY720 sequesters lymphocytes in secondary lymphoid organs through effects on sphingosine-1-phosphate (S1P) receptors. However, at higher doses than are required for immunosuppression, FTY720 also functions as an anticancer agent in multiple animal models. Our published work indicates that the anticancer effects of FTY720 do not depend on actions at S1P receptors but instead stem from FTY720s ability to restrict access to extracellular nutrients by down-regulating nutrient transporter proteins. This result was significant because S1P receptor activation is responsible for FTY720s dose-limiting toxicity, bradycardia, that prevents its use in cancer patients. Here, we describe diastereomeric and enantiomeric 3- and 4-C-aryl 2-hydroxymethyl pyrrolidines that are more active than the previously known analogues. Of importance is that these compounds fail to activate S1P1 or S1P3 receptors in vivo but retain inhibitory effects on nutrient transporter proteins and anticancer activity in solid tumor xenograft models. Our studies reaffirm that the anticancer activity of FTY720 does not depend upon S1P receptor activation and uphold the promise of using S1P receptor-inactive azacyclic FTY720 analogues in human cancer patients.